Prostatic acid phosphatase peptide-MHC complex (PAP-MHC)

Prostatic acid phosphatase (PAP) is a glycoprotein primarily produced by the prostate epithelium and is significantly overexpressed in prostate cancer cells (UniProt: P15309). When processed by the cell's proteasome, PAP-derived peptides are presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, specifically HLA-A2 in many clinical contexts (PubMed: 19440293). This peptide-MHC complex serves as a critical target for various immunotherapies, including the FDA-approved autologous cellular immunotherapy Sipuleucel-T, which aims to stimulate a T-cell response against PAP-expressing malignant cells (PubMed: 20660401). Beyond its role as an immunological target, PAP functions biologically as a phosphatase, though its exact physiological role in the prostate remains partially understood, involving the regulation of cell growth and nociception (PubMed: 19041769). In the context of oncology, the PAP-MHC complex is exploited to direct the immune system to recognize and eliminate prostate cancer cells while minimizing damage to non-prostatic tissues. Therapeutic strategies targeting this complex include dendritic cell vaccines, DNA vaccines, and engineered T-cell therapies (PubMed: 24615448).

Other names

ACPPProstatic acid phosphatasePAPProstatic acid phosphatase-derived peptide-HLA complexAcid phosphatase 2

Induction of a T-cell mediated immune response against cells expressing prostatic acid phosphatase (PAP) through the recognition of PAP-derived peptides presented on Major Histocompatibility Complex (MHC) molecules.